Aim To investigate the effect of umbilical cord-derived mesenchymal stem cells (UC-MSCs) administration among liver fibrosis experimental rat model via the regulation of angiotensin II type 1 receptor (AT1R) and platelet-derived growth factor-β (PDGF-β) due to their therapeutic potential to replace liver transplantation for advanced liver fibrosis. Yet the mechanism of action has been questionably associated with UC-MSCs fibrosis regression properties. Methods Sprague-Dawley (SD) rats (n=18) were separated into three groups (control, untreated liver fibrosis, and UC-MSCs treated group). Serum PDGF-β level was determined by enzymelinked immunosorbent assay (ELISA) following 14 days of UCMSCs injection. Meanwhile, AT1R expression was interpreted based on immunoreactive score (IRS) stained using polyclonal antibody and liver fibrosis stained with hematoxylin & eosin was graded using the METAVIR score. Results UC-MSCs were isolated successfully from rat umbilical cord. Liver fibrosis was observed following 14 weeks of CCl4 injection concurrent with higher serum level of PDGF-β, but the UC-MSCs-treated group had lower level (980.08 ±289.41 and 606.42±109.85 for untreated liver fibrosis and UC-MSCs treated group, respectively; p=0.004). There was also a high expression of AT1R among untreated liver fibrosis group, as well as highgrade liver fibrosis versus localized fibrosis and low level of AT1R expression among UC-MSCs treated-group (p=0.001). Conclusion UC-MSCs administration could ameliorate liver fibrosis by reducing the AT1R expression and PDGF-β serum levels, and intervention through this signaling pathway could be alternative evidence for the causative of positive outcome.
Friedman S. Liver fibrosis-from bench to bedside. J Hepatol. 2003. p. 38–53.
2.
Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res. 2018. p. 1–17.
3.
Asrani S, Devarbhavi H, Eaton J, Kamath P. Burden of liver diseases in the world. J hepatol. 2019. p. 151–71.
4.
Mokdad A, Lopez A, Shahraz S, Lozano R, Mokdad A, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014. p. 145.
5.
Liu Y, Wang Z, Kwong S, Lui E, Friedman S, Li F, et al. Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol. 2011. p. 612–25.
6.
Lei X, Fu W, Kaneyama J, Omoto T, Miyazaki T, Li B, et al. Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice. J Hepatol. 2016. p. 110–7.
7.
Hernandez-Gea V, Friedman S. Pathogenesis of liver fibrosis. Annu Rev Pathol Mech Dis. 2011. p. 425–56.
8.
Gressner A, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med. 2006. p. 76–99.
9.
Yoshida S, Ikenaga N, Liu S, Peng Z, Chung J, Sverdlov D, et al. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterol. 2014. p. 1378–92.
10.
Borkham-Kamphorst E, Weiskirchen R. The PDGF system and its antagonists in liver fibrosis. Cytokine Growth F R. 2016. p. 53–61.
11.
Yoshiji H, Kuriyama S, Yoshii J. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatol. 2001. p. 745–50.
12.
Bataller R, Ginès P, Nicolás J, Görbig M, Garcia-Ramallo E, Gasull X, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterol. 2000. p. 1149–56.
13.
Bataller R, Ginès SBP, Lora P, J, Solé AGA, Colmenero M, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterol. 2003. p. 117–25.
14.
Shim K, Eom Y, Kim M, Kang S, Baik S. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. Korean J Intern Med. 2018. p. 453–61.
15.
Zhang Y, Yang X, Wu P, Xu L, Liao G, Yang G. Expression of angiotensin II type 1 receptor in rat hepatic stellate cells and its effects on cell growth and collagen production. Horm Res. 2003. p. 105–10.
16.
Kanno K, Tazuma S, Chayama K. AT1R-deficient mice show less severe progression of liver fibrosis induced by CCl 4. Biochem Biophys Res Commun. 2003. p. 177–83.
17.
Forbes S, Gupta S, Dhawan A. Cell therapy for liver disease: from liver transplantation to cell factory. J Hepatol. 2015. p. 157–69.
18.
Raphael P, Mahou R, Morel P. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice. J Hepatol. 2015. p. 634–41.
19.
Yin F, Wang W, Jiang W. Human umbilical cord mesenchymal stem cells ameliorate liver fibrosis in vitro and in vivo: from biological characteristics to therapeutic mechanisms. World J Stem Cells. 2019. p. 548–64.
20.
Tsuchiya A, Takeuchi S, Watanabe T, Yoshida T, Nojiri S, Ogawa M, et al. Mesenchymal stem cell therapies for liver cirrhosis: MSCs as “conducting cells” for improvement of liver fibrosis and regeneration. Inflamm Regen. 2019. p. 1–6.
21.
Underwood W, Anthony R, Cartner S, Corey D, Grandin T, Greenacre C, et al. AVMA guidelines for the euthanasia of animals: 2013 edition. American Veterinary Medical Association; 2013.
22.
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatol. 1996. p. 289–93.
23.
Remmele W, Stegner H. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987. p. 138–40.
24.
Fortea J, Fernandez-Mena C, Puerto M, Ripoll C, Almagro J, Banares J, et al. Comparison of two protocols of carbon tetrachloride-induced cirrhosis in rats -improving yield and reproducibility. Sci Rep. 2018. p. 9163.
25.
Chen C, Li X, Wang L. Thymosin β4 alleviates cholestatic liver fibrosis in mice through downregulating PDGF/PDGFR and TGFβ/Smad pathways. Digest Liver Dis. 2020. p. 324–30.
26.
Lu B, Xu Y, Xu L, Cong X, Yin L, Li H, et al. Mechanism investigation of dioscin against CCl4 induced acute liver damage in mice. Environ Toxicol Phar. 2012. p. 127–35.
27.
Wang R, Wang J, Song F, Li S, Yuan Y. Tanshinol ameliorates CCl 4 induced liver fibrosis in rats through the regulation of Nrf2/HO-1 and NF-κB/ IκBα signaling pathway. Drug Des Dev Ther. 2018. p. 1281–92.
28.
Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact. 2011. p. 225–31.
29.
Perepelyuk M, Terajima M, Wang A, Georges P, Janmey P, Yamauchi M, et al. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol. 2013. p. 605–14.
30.
Foo N, Lin S, Lee Y, Wu M, Wang Y. Lipoic acid inhibits liver fibrosis through the attenuation of ROS-triggered signaling in hepatic stellate cells activated by PDGF and TGF-β. Toxicology. 2011. p. 39–46.
31.
Ezhilarasan D, Sokal E, Najimi M. Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets. Hepatobiliary Pancreat Dis Int. 2018. p. 192–7.
32.
Berardis S, Sattwika P, Najimi M, Sokal E. Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects. World J Gastroentero. 2015. p. 742.
33.
Sriramulu S, Banerjee A, Liddo D, Jothimani R, Gopinath G, Murugesan M, et al. Concise review on clinical applications of conditioned medium derived from human umbilical cordmesenchymal stem cells (UC-MSCs). Int J Hematol Oncol Stem Cell Res. 2018. p. 230.
34.
Zhang L, Peng X, Fang X, Li J, Chen H, Mao X. Human umbilical cord mesenchymal stem cells inhibit proliferation of hepatic stellate cells in vitro. Int J Mol Med. 2018. p. 2545–52.
35.
Putra A, Antari A, Retnokustiyah A, Sorayanurintan Y, Anna C, Sadyah N, et al. Mesenchymal stem cells accelerate liver regeneration in acute liver failure animal model. Biomed Res Ther. 2018. p. 2802–10.
36.
Munshi M, Uddin M, Glaser S. The role of the renin-angiotensin system in liver fibrosis. Exp Biol Med. 2011. p. 557–66.
37.
Okamoto K, Tajima H, Nakanuma S, Sakai S, Makino I, Kinoshita J, et al. Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma. Int J Oncol. 2012. p. 573–82.
38.
Moreno M, Bataller R. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin Liver Dis. 2008. p. 825–52.
39.
Yong K, Li Y, Liu F, Gao B, Lu T, Abas W, et al. Paracrine effects of adipose-derived stem cells on matrix stiffness-induced cardiac myofibroblast differentiation via angiotensin II type 1 receptor and Smad7. Sci Rep. 2016. p. 33067.
40.
Alfaifi M, Eom Y, Newsome P, Baik S. Mesenchymal stromal cell therapy for liver diseases. J Hepatol. 2018. p. 1272–85.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
